Type of Study: Epidemiological

Sponsor / Support: LACOG

Primary Objectives: The LACOG 0121 study will describe the rate of patients with 68Ga-PSMA-PET positive lesions [defined as the presence of lesions with 68Ga-PSMA uptake in the prostate (biochemical recurrence) and/or in extra-prostatic sites (localized disease and biochemical recurrence) in patients with no detected lesions in conventional imaging].

Design: This is an observational, retrospective study of patients with diagnosis of prostate cancer with no detection of extra-prostatic disease in traditional imaging who underwent 68Ga-PSMA-PET imaging in localized disease and biochemical recurrence during October 2015 and January 2021.

Sample Size: 700 patients

Principal Investigator: Andrey Soares

Countries LATAM: Brazil

Clinicaltrials.gov Identifier: NCT05169372